retatrutide phase 2 trial obesity nejm 2023 triple agonist Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Triple G Agonists – Retatrutide.

In the future, a multidimensional line of evidence is needed to clarify the source of GLP-1RA effects in IBD, including in vitro experiments to confirm direct actions, animal models designed to exclude metabolic interference, and clinical data adjusted for metabolic confounders

Each improperly discarded needle puts our drivers and sorters at risk

Although the company might not be widely recognized across all sectors, its commitment to quality and consumer satisfaction is evident through its focus on research and development

[1] Serious but rare risks include pancreatitis, gallbladder disease, acute kidney injury (usually secondary to dehydration from gastrointestinal losses), and hypersensitivity reactions

The Mayo Clinic cohort: women on semaglutide plus HRT lost more weight at every timepoint (and it wasnt explained by confounders)